Process performance of cervical screening programmes in Europe

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Process performance of cervical screening programmes in Europe. / Ronco, Guglielmo; Ballegooijen, Marjolein van; Becker, Nikolaus; Chil, Arkadiusz; Fender, Muriel; Giubilato, Pamela; Kurtinaitis, Juozas; Lancucki, Lesz; Lynge, Elsebeth; Morais, Antonio; O'Reilly, Marian; Sparen, Pär; Suteu, Ofelia; Rebolj, Matejka; Veerus, Piret; Zakelj, Maja Primic; Anttila, Ahti.

In: European Journal of Cancer, 2009.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Ronco, G, Ballegooijen, MV, Becker, N, Chil, A, Fender, M, Giubilato, P, Kurtinaitis, J, Lancucki, L, Lynge, E, Morais, A, O'Reilly, M, Sparen, P, Suteu, O, Rebolj, M, Veerus, P, Zakelj, MP & Anttila, A 2009, 'Process performance of cervical screening programmes in Europe', European Journal of Cancer. https://doi.org/10.1016/j.ejca.2009.07.022

APA

Ronco, G., Ballegooijen, M. V., Becker, N., Chil, A., Fender, M., Giubilato, P., ... Anttila, A. (2009). Process performance of cervical screening programmes in Europe. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2009.07.022

Vancouver

Ronco G, Ballegooijen MV, Becker N, Chil A, Fender M, Giubilato P et al. Process performance of cervical screening programmes in Europe. European Journal of Cancer. 2009. https://doi.org/10.1016/j.ejca.2009.07.022

Author

Ronco, Guglielmo ; Ballegooijen, Marjolein van ; Becker, Nikolaus ; Chil, Arkadiusz ; Fender, Muriel ; Giubilato, Pamela ; Kurtinaitis, Juozas ; Lancucki, Lesz ; Lynge, Elsebeth ; Morais, Antonio ; O'Reilly, Marian ; Sparen, Pär ; Suteu, Ofelia ; Rebolj, Matejka ; Veerus, Piret ; Zakelj, Maja Primic ; Anttila, Ahti. / Process performance of cervical screening programmes in Europe. In: European Journal of Cancer. 2009.

Bibtex

@article{49c67f009c6c11debc73000ea68e967b,
title = "Process performance of cervical screening programmes in Europe",
abstract = "Standardised tables of aggregated data were collected from 15 European national or regional cervical screening programmes and key performance indicators computed as reported in European Union (EU) Guidelines, 2nd edition. Cytological results varied widely between countries both for the total proportion of abnormal tests (from 1.2{\%} in Germany (Mecklenburg-Vorpommern) to 11.7{\%} in Ireland-Midwest Region) and for their distribution by grade. Referral rates for repeat cytology (ranging from 2.9{\%} of screened women in the Netherlands to 16.6{\%} in Slovenia) or for colposcopy (ranging from 0.8{\%} in Finland to 4.4{\%} in Romania-Cluj) and the Positive Predictive Value (PPV) of colposcopic attendance (ranging from 8{\%} in Romania-Cluj to 52{\%} in Lithuania) were strongly influenced by management protocols, in particular for atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion (LSIL) cytology. However, cytology-specific PPV also showed remarkable variability. The detection rate of CIN2+ histology ranged from <0.1{\%} in of poland screened to women>1{\%} in England and Denmark. Low attendance for colposcopy after referral was observed in some east-European countries. These comparisons may be useful for improving the performance of cervical screening in general and more so if new screening technologies and vaccination for Human Papillomavirus are introduced. Overall, quality was better in countries that have operated organised programmes for a longer time, plausibly as a result of long-lasting monitoring and quality assurance activities. Therefore, the availability of these data, the first comparing European countries, and the increased number of countries that can provide such data (only five in 2004) represent progress. Nevertheless, there is a clear need to standardise the cytological and histological classifications used in screening, as well as data registration systems across Europe.",
author = "Guglielmo Ronco and Ballegooijen, {Marjolein van} and Nikolaus Becker and Arkadiusz Chil and Muriel Fender and Pamela Giubilato and Juozas Kurtinaitis and Lesz Lancucki and Elsebeth Lynge and Antonio Morais and Marian O'Reilly and P{\"a}r Sparen and Ofelia Suteu and Matejka Rebolj and Piret Veerus and Zakelj, {Maja Primic} and Ahti Anttila",
year = "2009",
doi = "10.1016/j.ejca.2009.07.022",
language = "English",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Pergamon",

}

RIS

TY - JOUR

T1 - Process performance of cervical screening programmes in Europe

AU - Ronco, Guglielmo

AU - Ballegooijen, Marjolein van

AU - Becker, Nikolaus

AU - Chil, Arkadiusz

AU - Fender, Muriel

AU - Giubilato, Pamela

AU - Kurtinaitis, Juozas

AU - Lancucki, Lesz

AU - Lynge, Elsebeth

AU - Morais, Antonio

AU - O'Reilly, Marian

AU - Sparen, Pär

AU - Suteu, Ofelia

AU - Rebolj, Matejka

AU - Veerus, Piret

AU - Zakelj, Maja Primic

AU - Anttila, Ahti

PY - 2009

Y1 - 2009

N2 - Standardised tables of aggregated data were collected from 15 European national or regional cervical screening programmes and key performance indicators computed as reported in European Union (EU) Guidelines, 2nd edition. Cytological results varied widely between countries both for the total proportion of abnormal tests (from 1.2% in Germany (Mecklenburg-Vorpommern) to 11.7% in Ireland-Midwest Region) and for their distribution by grade. Referral rates for repeat cytology (ranging from 2.9% of screened women in the Netherlands to 16.6% in Slovenia) or for colposcopy (ranging from 0.8% in Finland to 4.4% in Romania-Cluj) and the Positive Predictive Value (PPV) of colposcopic attendance (ranging from 8% in Romania-Cluj to 52% in Lithuania) were strongly influenced by management protocols, in particular for atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion (LSIL) cytology. However, cytology-specific PPV also showed remarkable variability. The detection rate of CIN2+ histology ranged from <0.1% in of poland screened to women>1% in England and Denmark. Low attendance for colposcopy after referral was observed in some east-European countries. These comparisons may be useful for improving the performance of cervical screening in general and more so if new screening technologies and vaccination for Human Papillomavirus are introduced. Overall, quality was better in countries that have operated organised programmes for a longer time, plausibly as a result of long-lasting monitoring and quality assurance activities. Therefore, the availability of these data, the first comparing European countries, and the increased number of countries that can provide such data (only five in 2004) represent progress. Nevertheless, there is a clear need to standardise the cytological and histological classifications used in screening, as well as data registration systems across Europe.

AB - Standardised tables of aggregated data were collected from 15 European national or regional cervical screening programmes and key performance indicators computed as reported in European Union (EU) Guidelines, 2nd edition. Cytological results varied widely between countries both for the total proportion of abnormal tests (from 1.2% in Germany (Mecklenburg-Vorpommern) to 11.7% in Ireland-Midwest Region) and for their distribution by grade. Referral rates for repeat cytology (ranging from 2.9% of screened women in the Netherlands to 16.6% in Slovenia) or for colposcopy (ranging from 0.8% in Finland to 4.4% in Romania-Cluj) and the Positive Predictive Value (PPV) of colposcopic attendance (ranging from 8% in Romania-Cluj to 52% in Lithuania) were strongly influenced by management protocols, in particular for atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion (LSIL) cytology. However, cytology-specific PPV also showed remarkable variability. The detection rate of CIN2+ histology ranged from <0.1% in of poland screened to women>1% in England and Denmark. Low attendance for colposcopy after referral was observed in some east-European countries. These comparisons may be useful for improving the performance of cervical screening in general and more so if new screening technologies and vaccination for Human Papillomavirus are introduced. Overall, quality was better in countries that have operated organised programmes for a longer time, plausibly as a result of long-lasting monitoring and quality assurance activities. Therefore, the availability of these data, the first comparing European countries, and the increased number of countries that can provide such data (only five in 2004) represent progress. Nevertheless, there is a clear need to standardise the cytological and histological classifications used in screening, as well as data registration systems across Europe.

U2 - 10.1016/j.ejca.2009.07.022

DO - 10.1016/j.ejca.2009.07.022

M3 - Journal article

C2 - 19713100

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -

ID: 14277641